DrugPatentWatch Database Preview

Novartis Pharms Company Profile

NOVARTIS PHARMS has sixty approved drugs.

There are one hundred and twelve US patents protecting NOVARTIS PHARMS drugs.

There are one thousand seven hundred and ninety-seven patent family members on NOVARTIS PHARMS drugs in sixty-eight countries and one hundred and seventy-one supplementary protection certificates in fifteen countries.

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003	AT1	RX	Yes	Yes	6,716,830*PED	➤ Sign Up			Y	➤ Sign Up
Novartis Pharms Corp	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-003	Sep 8, 2009		RX	Yes	Yes	7,160,870*PED	➤ Sign Up			Y	➤ Sign Up
Novartis Pharms Corp	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-004	Oct 20, 2011		RX	Yes	No	7,790,704*PED	➤ Sign Up			Y	➤ Sign Up
Novartis Pharms Corp	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	9,155,706	➤ Sign Up	Y			➤ Sign Up
Novartis Pharms Corp	FARYDAK	panobinostat lactate	CAPSULE;ORAL	205353-002	Feb 23, 2015		RX	Yes	No	6,552,065	➤ Sign Up	Y	Y		➤ Sign Up
Novartis Pharms Corp	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007		RX	Yes	Yes	7,157,466	➤ Sign Up	Y	Y		➤ Sign Up
Novartis Pharms Corp	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	6,503,497	➤ Sign Up
Novartis Pharms Corp	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003	5,849,752*PED	➤ Sign Up
Novartis Pharms Corp	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-003	Aug 27, 1999	5,578,628*PED	➤ Sign Up
Novartis Pharms Corp	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-001	Dec 31, 1992	4,753,789*PED	➤ Sign Up
Novartis Pharms Corp	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998	4,670,444*PED	➤ Sign Up
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,596,750	➤ Sign Up
Novartis Pharms Corp	ARRANON	nelarabine	INJECTABLE;INTRAVENOUS	021877-001	Oct 28, 2005	5,821,236	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Ophthalmic Solution	0.003%	➤ Subscribe	2015-12-30
➤ Subscribe	Ophthalmic Solution	0.20%	➤ Subscribe	2008-09-08
➤ Subscribe	Ophthalmic Solution	0.7%	➤ Subscribe	2015-09-10
➤ Subscribe	Ophthalmic	0.50%	➤ Subscribe	2005-12-22
➤ Subscribe	Ophthalmic Suspension	0.3%	➤ Subscribe	2015-12-21
➤ Subscribe	Tablets	90 mg and 360 mg	➤ Subscribe	2015-10-19
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2006-03-02
➤ Subscribe	Tablets	180 mg	➤ Subscribe	2016-04-28
➤ Subscribe	Injection	100 mg/mL, 2.5 mL vials	➤ Subscribe	2007-09-24
➤ Subscribe	Tablets	12.5 mg and 25 mg	➤ Subscribe	2014-02-04
➤ Subscribe	Oral Solution	4 mg/5 mL	➤ Subscribe	2004-12-20
➤ Subscribe	Ophthalmic Solution	10.5%	➤ Subscribe	2012-02-29
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-07-17
➤ Subscribe	Ophthalmic Solution	0.00%	➤ Subscribe	2009-02-19
➤ Subscribe	Nasal Spray	0.665 mg/ Spray	➤ Subscribe	2009-06-29
➤ Subscribe	Otic Suspension	0.3%/0.1%	➤ Subscribe	2012-07-31
➤ Subscribe	Tablets	180 mg	➤ Subscribe	2015-10-23
➤ Subscribe	Ophthalmic Emulsion	0.05%	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	50 mg and 75 mg	➤ Subscribe	2014-01-07
➤ Subscribe	Injection	1 mg/mL, 50 mL vials	➤ Subscribe	2011-12-16
➤ Subscribe	Tablets	250 mg	➤ Subscribe	2011-03-14

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014 00038	Denmark	➤ Sign Up	PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
0763	Netherlands	➤ Sign Up	PRODUCT NAME: CERITINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/999 20150508
0917	Netherlands	➤ Sign Up	PRODUCT NAME: MIDOSTAURINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/17/1218 20170920
2012 00024	Denmark	➤ Sign Up
024	Luxembourg	➤ Sign Up	92024, EXPIRES: 20260730
07C/063	Belgium	➤ Sign Up	PRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070823
2012017,C1920764	Lithuania	➤ Sign Up	PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.